RxDoctor Payments DataLook up a doctor →

Steven Madden, MD

Hematology & Oncology · West Columbia, SCNPI 1538198171

Payments from drug & device makers

$334,843in general payments, 2019–2025

Across 444 payments — averaging $754.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$198K
  • AstraZeneca$60K
  • Jazz Pharmaceuticals Inc.$45K
  • Amgen$16K
  • Veru Inc.$8K
  • Merck$4K
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$3,20298%
  • Education$672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$334,843 in reported general payments places this provider in the 80th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina

Medicare billing

Part B allowed, 2024
$6,141,014
Medicare patients
1,677
Services billed
266,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide100$1,762,038
IbrancePalbociclib58$921,047
ImbruvicaIbrutinib53$792,467
CalquenceAcalabrutinib Maleate43$738,216
Lenalidomide45$685,143
TagrissoOsimertinib Mesylate40$661,824
OrserduElacestrant Hcl28$632,034
PomalystPomalidomide23$541,947
Abiraterone Acetate156$523,161
XtandiEnzalutamide51$520,852
SprycelDasatinib18$303,607
VerzenioAbemaciclib18$279,520
LynparzaOlaparib12$191,810
Imatinib Mesylate85$163,077
KisqaliRibociclib Succinate12$158,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$213$1,762,038100 claims
AstraZenecaCalquence, Tagrisso, Lynparza$60,360$1,591,85095 claims
PfizerIbrance, Eliquis$197,697$1,049,412255 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$189$845,55441 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$20$792,46753 claims
Stemline Therapeutics Inc.Orserdu$50$632,03428 claims
Astellas Pharma US IncXtandi$38$520,85251 claims
Lilly USA, LLCVerzenio$60$279,52018 claims
NovartisKisqali$1,508$158,94812 claims
Johnson & JohnsonXarelto$177$25,58437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 166 hematology & oncology providers in South Carolina.

Other hematology & oncology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →